Do ace inhibitors cause vasodilation
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors and Vasodilation: Mechanisms and Effects
Introduction to ACE Inhibitors and Vasodilation
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications commonly used to treat conditions such as hypertension and heart failure. One of their key effects is vasodilation, which is the widening of blood vessels. This article explores the mechanisms through which ACE inhibitors induce vasodilation and their impact on endothelial function.
Mechanisms of ACE Inhibitor-Induced Vasodilation
Bradykinin Potentiation
A significant mechanism by which ACE inhibitors cause vasodilation is through the potentiation of bradykinin, an endogenous vasodilator peptide. ACE inhibitors prevent the breakdown of bradykinin, leading to increased levels of this peptide, which in turn stimulates the release of nitric oxide (NO) from endothelial cells, causing vasodilation Auch‐Schwelk1993Auch‐Schwelk1995Auch‐Schwelk1993. Studies have shown that ACE inhibitors like lisinopril and captopril enhance the vasodilatory response to bradykinin in both bovine and human coronary arteries Auch‐Schwelk1993Auch‐Schwelk1995.
Nitric Oxide Release
The release of NO is a crucial factor in the vasodilatory effect of ACE inhibitors. NO is a potent vasodilator that relaxes the smooth muscles of blood vessels. Research indicates that ACE inhibitors increase the availability of NO by preventing its degradation and enhancing its production in response to bradykinin Auch‐Schwelk1995Auch‐Schwelk1993. This effect is particularly evident in the presence of endothelium, as the removal of endothelial cells or inhibition of NO synthase negates the vasodilatory effects of ACE inhibitors Auch‐Schwelk1993Auch‐Schwelk1995.
Clinical Evidence of Vasodilation by ACE Inhibitors
Improvement in Endothelial Function
Several studies have demonstrated that ACE inhibitors improve endothelial function, which is often impaired in conditions like diabetes and hypertension. For instance, in patients with type 1 diabetes and microalbuminuria, short-term treatment with ACE inhibitors such as captopril and enalapril significantly improved endothelium-dependent vasodilation in the femoral artery . Similarly, in type 2 diabetic patients, enalapril enhanced both stimulated and basal NO-dependent endothelial function .
Effects in Hypertensive Patients
In hypertensive patients, ACE inhibitors have been shown to restore the vasodilator potency of endothelium-derived relaxing factors. For example, in spontaneously hypertensive rats, treatment with captopril or enalapril restored the diminished vasodilator response to acetylcholine and L-S-nitrosocysteine, indicating a reduction in oxidative stress and improved endothelial function .
Role in Heart Failure
In patients with heart failure, chronic ACE inhibitor therapy has been associated with enhanced vasodilation due to increased bradykinin activity. This effect is mediated through the B1 receptor and contributes to the maintenance of basal vascular tone .
Conclusion
ACE inhibitors induce vasodilation primarily through the potentiation of bradykinin and the subsequent release of nitric oxide from endothelial cells. This mechanism not only helps in lowering blood pressure but also improves endothelial function in various cardiovascular conditions. The clinical benefits of ACE inhibitors in enhancing vasodilation underscore their importance in the management of hypertension, heart failure, and diabetes-related vascular dysfunction.
Sources and full results
Most relevant research papers on this topic